Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Aug
17
2020
County Zoning Ordinance Cannot be Used to Justify Property Seizure Sheppard, Mullin, Richter & Hampton LLP
Sep
16
2020
Latest Update on FDA’s Software Pre-Cert Pilot Program Sheppard, Mullin, Richter & Hampton LLP
May
10
2021
Waiver Of Intellectual Property Protections For COVID-19 Vaccine Unlikely To Have Meaningful Impact In Short Term Sheppard, Mullin, Richter & Hampton LLP
Jun
17
2021
Delaware Court of Chancery Decision Provides Guidance on M&A Earnouts Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2013
Delaware Supreme Court Affirms Preclusive Effect of Non-Delaware Dismissals and Rejects Irrebuttable Presumption That a Derivative Plaintiff Who Fails to Conduct a Section 220 Inspection Is an Inadequate Representative Sheppard, Mullin, Richter & Hampton LLP
May
2
2013
Can California Cap and Trade if Brussels Stumbles? Sheppard, Mullin, Richter & Hampton LLP
Jul
28
2021
What Do I Do With My Workplace Drug Policy Now That Cannabis Is Legal in Illinois and My Employees Are Remote? Sheppard, Mullin, Richter & Hampton LLP
Apr
13
2018
Health Plans and Pharmacy Benefit Managers – Past and Future Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2013
Details: Highlights from the August & September 2013 Federal Register Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2021
NYC Council Passes Bill Granting Paid Sick Leave to Parents Vaccinating Children Against COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Dec
21
2021
White May Not Be the Trend in 2022: EU Bans Whitening Food additive E171 as of January 1, 2022 Sheppard, Mullin, Richter & Hampton LLP
Nov
29
2018
CMS Issues Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2014
Preexisting Management Plan Not a “Mitigation Measure” for Purposes of California Environmental Quality Act (CEQA) Exemption Sheppard, Mullin, Richter & Hampton LLP
May
31
2022
Digital Health in the Metaverse: Three Legal Considerations Sheppard, Mullin, Richter & Hampton LLP
Apr
25
2019
Years in the Making: The Health Resources & Services Administration Launches a Website to Increase Pricing Transparency in the 340B Program Sheppard, Mullin, Richter & Hampton LLP
Oct
24
2014
FTC Takes Action Against Unsubstantiated Caffeine-Infused Shapewear Weight-Loss Claims Sheppard, Mullin, Richter & Hampton LLP
Sep
21
2022
In One Day, California Governor Signs Into Law Ten Cannabis Bills, Including Authorization for Interstate Commerce Sheppard, Mullin, Richter & Hampton LLP
Jun
3
2019
The U.S. Trademark Office Opens The Door to Registering Certain Cannabis Trademarks Sheppard, Mullin, Richter & Hampton LLP
Mar
4
2015
Ascertainability Saps Plaintiffs’ Energy in Dietary Supplement Class Action Sheppard, Mullin, Richter & Hampton LLP
Mar
21
2023
California’s Toxic-Free Cosmetics Act Bans 24 Ingredients From Cosmetic Products Sheppard, Mullin, Richter & Hampton LLP
Jun
15
2023
Access to Abortion Pill on the Precipice: A Deep Dive into the Federal Court Rulings that will Decide the Fate of Mifepristone Sheppard, Mullin, Richter & Hampton LLP
Nov
13
2023
CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2016
Forget About Vermont!: Congress Passes GMO “Labeling” Legislation Sheppard, Mullin, Richter & Hampton LLP
Nov
18
2020
Green Wave: The Latest Election Cycle Brings Hope for Standardized Cannabis Legalization Sheppard, Mullin, Richter & Hampton LLP
Nov
23
2020
Los Angeles County Restricts In-Person Dining Due to Surge in COVID-19 Cases Sheppard, Mullin, Richter & Hampton LLP
Dec
12
2011
FDA Announces Proposals for Biosimilars User Fees and Performance Review Goals Sheppard, Mullin, Richter & Hampton LLP
Apr
29
2021
“Buy American” Update: Essential Medicines May Continue to Come From Abroad (For Now) Sheppard, Mullin, Richter & Hampton LLP
Apr
17
2013
Utility Pole Not A Point Source Under The Clean Water Act Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins